论文信息 - O4 Tivozanib hydrochloride versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from the Phase III randomized, open-label, multicenter TIVO-1 trial - 字舞流文

O4 Tivozanib hydrochloride versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from the Phase III randomized, open-label, multicenter TIVO-1 trial

R. Motzer | A. Berkenblit | C. Sternberg | A. Strahs | W. Slichenmyer | C. Szczylik | P. Tomczak | B. Alekseev | Thomas E. Hutson | J. Zhang | V. Jinga | O. Lipatov | D. Nosov | T. Eisen | M. Hârza | B. Esteves | O. Lyulko